|
Dr. Schreiner joined Raven in May 2006. He is experienced in all phases of drug development, from discovery through clinical development to commercial launch. Prior to joining Raven, Dr. Schreiner was Chief Scientific Officer and Chief Medical Officer at Scios until its acquisition by Johnson & Johnson, whereupon he was named President. In that capacity, he oversaw research and development programs at Scios in cardiovascular disease, inflammation, and oncology. He served on the Pharmaceutical Research and Development Committee for Johnson & Johnson and chaired its Early Research and Development Committee. Dr. Schreiner received his M.D. from Harvard Medical School and his Ph.D. in Immunology from Harvard University. He trained in Internal Medicine and Nephrology at the Brigham and Women’s Hospital in Boston. He held joint appointments on the faculties of the Department of Medicine and Pathology at Harvard Medical School and the Washington University School of Medicine, where he received tenure. He was one of the founding scientists at CV Therapeutics where he served as Vice President of Medical Science and Preclinical Research. | 